Quick Summary
del-IMMUNE V® is currently being evaluated in an ongoing clinical research study involving patients undergoing colorectal cancer surgery. Conducted in collaboration with a major surgical hospital in Havana, Cuba, the study explores the potential role of del-IMMUNE V® supplementation during the pre- and post-operative periods. Researchers are examining inflammatory biomarkers, microbiome balance, and indicators associated with patient recovery. Formal peer-reviewed publication of the study findings is expected in the coming months.
Overview of the Clinical Research
Stellar Biotics’ del-IMMUNE V® is being evaluated in a clinical research study involving patients undergoing surgery for colorectal cancer across multiple stages of the disease.
The study is being conducted in collaboration with Hermanos Ameijeiras Surgical Clinical Hospital in Havana, Cuba. Researchers are examining the potential role of del-IMMUNE V® as a nutritional supplement during both the pre-operative and post-operative phases of colorectal surgery.
The research focuses on biological markers related to inflammation, microbiome balance, and other indicators commonly monitored during surgical recovery.
Study Design
Participants in the study received two daily doses of 100 mg of del-IMMUNE V® (200 mg total) beginning seven days prior to surgery and continuing for 60 days following the procedure.
Throughout the study period, researchers monitored several biological markers associated with inflammatory response and post-surgical recovery.
Following colorectal surgery, clinicians commonly evaluate biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6) to assess inflammation levels and recovery progression. These markers can provide insight into how the body responds during the post-operative healing process.
Safety Observations
Within the observed study population, supplementation with del-IMMUNE V® was well tolerated and demonstrated a safety profile comparable to placebo. Researchers also noted that supplementation did not interfere with standard post-surgical treatments such as adjuvant chemotherapy.
Microbiome and Inflammation Research
Early observations from the research are exploring how perioperative supplementation with del-IMMUNE V® may support a balanced gut microbiome and healthy inflammatory responses. Researchers continue to evaluate changes in biomarkers including IL-6, CRP, and CEA alongside patient-reported recovery indicators.
The gut microbiome plays an important role in overall immune balance and digestive health. Beneficial gut bacteria may produce compounds known as short-chain fatty acids (SCFAs), which help support normal gut function and healthy immune activity.
Research in the Context of Surgical Recovery
Researchers are also examining how nutritional supplementation may be used alongside established surgical recovery approaches, including Enhanced Recovery After Surgery (ERAS) protocols. These protocols are widely used to support recovery experiences following colorectal surgery.
The goal of the ongoing research is to better understand how microbiome-focused nutritional strategies may complement existing recovery practices in surgical settings.
Publication Status
Peer review and formal publication of the study findings are expected in the coming months. As additional analyses are completed and published, further details regarding the research outcomes may become available.
Frequently Asked Questions
What is del-IMMUNE V®?
del-IMMUNE V® is a proprietary immune-support ingredient derived from a probiotic bacterial strain. It is designed to help support immune balance and microbiome health.
What is the goal of the current clinical research?
The study is exploring how del-IMMUNE V® supplementation may relate to inflammatory biomarkers, microbiome balance, and patient recovery indicators surrounding colorectal surgery.
Where is the clinical study being conducted?
The research is being conducted in collaboration with Hermanos Ameijeiras Surgical Clinical Hospital in Havana, Cuba.
Has the study been published?
The study is currently undergoing peer review, and formal publication is expected in the coming months.
Does this research mean del-IMMUNE V® treats or prevents disease?
No. The research described above is exploratory and is intended to evaluate biological markers and recovery indicators in a clinical research setting. del-IMMUNE V® is a dietary supplement ingredient and is not intended to diagnose, treat, cure, or prevent any disease.
